Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

Can Cinderella save us?

Study finds antibiotic resistant bacteria can migrate from gut to lungs

Eliminating AMR pathogens from the gut microbiome of patients could prevent infections

- PMLiVE

Novartis and MMV to advance new malaria drug combination to phase 3 study

The announcement comes as the threat of resistance to current malaria treatments grows

- PMLiVE

Precision medicine trial opens for patients with rare cancers

Rare cancers make up 22% of cancers that are diagnosed globally each year, more than any single type of cancer

- PMLiVE

Kate Shaw reflects on Innovative Trials’ first US office openings

On Thanksgiving, Kate Shaw, Founder and CEO of Innovative Trials, reflects on the company first US office opening

Innovative Trials

- PMLiVE

Reimagining strategy development for a hybrid workforce

By Janice MacLennan

CALM_Invisible_Opponent_KV_Press_Release

Declan Rice features in new campaign for suicide prevention charity Campaign Against Living Miserably

New CALM campaign fronted by West Ham and England footballer aims to tackle loneliness

SEVEN STONES COLLECTIVE

regeneron headquarters

Regeneron’s Libtayo granted EC approval for recurrent or metastatic cervical cancer

A phase 3 trial demonstrated a 31% reduction in the risk of death compared to chemotherapy

- PMLiVE

AbbVie’s Skyrizi receives EC approval for active Crohn’s disease

The approval makes Skyrizi the first specific IL-23 inhibitor as a Crohn's treatment in the EU

- PMLiVE

Merck’s Keytruda meets primary endpoint in phase 3 gastric cancer trial

Gastric cancer is the fourth leading cause of cancer death worldwide

Can Cinderella save us?

UK government launches consultation on silent AMR pandemic

The consultation will call upon the latest data from experts on antimicrobial resistance

- PMLiVE

FDA approves first gene therapy for adults with haemophilia B

CSL’s Hemgenix allowed patients to produce mean factor IX activity of 39% at six months

- PMLiVE

Porterhouse Medical US celebrates 5 years of working in harmony with our client partners

Globally acclaimed healthcare communications and medical insights network, Porterhouse Medical Group, is delighted to announce that our US-based team is celebrating its fifth anniversary this month. Porterhouse Medical US was...

Porterhouse Medical Group

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links